patterns of core and levator ani muscles during exoskeleton-assisted over ground walking vs treadmill walking with body-weight support in motor complete SCI vs able bodied controls.
INTRODUCTION AND OBJECTIVES:
Little is known about the relative quality of life (QoL) benefits of different bladder management strategies after spinal cord injury (SCI). We sought to describe bladderrelated symptoms and QoL using a national sample of SCI patients.
METHODS: Data from a national prospective observational survey was used. Demographic and clinical information were obtained by interview. The Neurogenic Bladder Symptom Score (NBSS), a validated tool to measure urinary symptoms, was administered electronically. Patient demographics, NBSS total score and the NBSS QoL question ("If you had to live the rest of your life with the way your bladder (or urinary reservoir) currently works, how would you feel?") were compared with bladder management method using chi-squared, Fisher 0 s exact, ANOVA and Kruskal-Wallis tests as appropriate.
RESULTS: Since January 2016, 780 participants completed the baseline interview. Median age was 46 (interquartile range, IQR: 35-56) with median 27 (IQR: 20-41) years since injury. 39% of participants were recruited in clinic and 55% online/remote. SCI level was: 49% paraplegia, 43% tetraplegia, and 8% unknown/other. Current bladder management was: 63% clean-intermittent catheterization (CIC), 23% indwelling suprapubic/urethral catheter or stoma, 9% spontaneous voiding, and 5% condom catheter. Those using CIC were significantly younger than those using other bladder management methods (p<0.001) and those using spontaneous voiding had the longest median time since injury (p<0.001). The total NBSS score was lowest for indwelling catheter/stoma (18.3 AE 10.5) as compared to condom catheter (22.9 AE 9.3), CIC (24.5 AE 9.9) and spontaneous voiding (28.1 AE 11.9) (p <0.001). Similarly, bladder QoL was 00 pleased 00 or 00 mostly satisfied 00 in 43% of people with an indwelling catheter/stoma, 35% for CIC, 27% for condom catheter, and 26% for spontaneously voiding (chi-square test with permutation, p¼0.012; Figure 1 ). CONCLUSIONS: In a large cohort of SCI patients, indwelling catheters or stoma drainage was associated with reduced bladderrelated symptoms and consequences and best QoL among bladder management methods. This patient-centered outcome differs from the urologists preference for CIC based on medical benefits. Further exploration is needed to understand the patient-reported QoL and clinical outcomes. 
Source of Funding

INTRODUCTION AND OBJECTIVES:
To assess the outcomes of switching to a different brand of botulinum toxin A (BTA), from Onabotulinum toxin A (OTA) (Botox) to abobotulinum toxin A (ATA) (Dysport) in case of failure of intradetrusor injections (IDI) of OTA in the treatment of neurogenic detrusor overactivity (NDO). Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1261 METHODS: The charts of all patients who underwent a switch to IDI of ATA after failure of an IDI of OTA at six departments of neurourology were retrospectively reviewed. The main outcomes of interest were the bladder diary data and four urodynamic parameters: maximum cystometric capacity (MCC), maximum detrusor pressure (PDET max) and volume at first uninhibited detrusor contraction (UDC). Data were compared before and after treatment with OTA and ATA, using Stuart, Wilcoxon and paired-t tests for paired samples and univariate logistic regression was performed to seek for predictors of switch success.
RESULTS: Out of 57 patients included, 38.6% were primary non-responders to Botox, and in secondary non-responder a median number of 5 OTA IDI were performed before failure (range 1-17). Persistent urinary incontinence was observed in 84.2% patients, and 75.4% had persistent detrusor overactivity. Six weeks after the first injection of Dysport, no adverse events were reported. A significant decrease in number of urinary incontinence episodes per day was observed in 52.63% of patients (p <0.001) and all patients experienced a reduction in PDET Max (-8.1 cmH20 on average; p¼0.003). MCC significantly increased by a mean of 41.2 ml (p¼0.02). The proportion of patients with no UDC increased significantly at after ATA injections (from 15.79% to 43.9%; p¼0.0002). Hence, 32 patients draw clinical and/or urodynamic benefits from the botulinum toxin switch from OTA to ATA (56.14%). After a median follow up of 21 months, 87% of responders to BTA switch were still treated successfully with BTA. In univariate analysis, three variables were associated with BTA switch success: low MCC before first ATA IDI (OR¼20.4;p¼0.01) and dose of ATA (OR¼ 10.9; p¼0.048) were predictive of increased success rates; poor compliance was predictive of lower success rate (OR¼0.2; p¼0.04).
CONCLUSIONS: Most patients refractory to OTA (Botox) (56.14%) draw benefits from the switch to ATA (Dysport). Low MCC and dose of ATA were predictive of success of BTA switch while poor compliance was predictive of failure.
Source of Funding: none
PD64-06
MULTI-INSTITUTIONAL EXPERIENCE WITH ONABOTULINUMTOXIN-A IN PATIENTS WITH PRIOR AUGMENTATION CYSTOPLASTY
Laura Martinez*, Houston, TX; Ryan Tubre, Kansas City, KS; Robyn Roberts, Galveston, TX; Timothy Boone, Julie Stewart, Houston, TX; Tomas Griebling, Kansas City, KS; Rose Khavari, Houston, TX; Priya Padmanabhan, Kansas City, KS INTRODUCTION AND OBJECTIVES: Augmentation cystoplasty has been used in the treatment of refractory neurogenic and overactive bladder. In some patients, symptoms may persist or recur after the surgery, and there is little guidance on management in this setting. In this study, we reviewed the use of Onabotulinum Toxin A (BTX-A) in patients with prior bladder augmentation.
METHODS: Retrospective chart review was performed at two institutions, identifying patients with history of augmentation cystoplasty who underwent intravesical BTX-A injection. Data collected included demographics, preoperative and postoperative findings.
RESULTS: 22 (17 female, 5 male) patients with mean age 36.8 years (range 18-65) and history of prior augmentation cystoplasty were identified. Etiology of bladder dysfunction included: congenital neurogenic bladder (59%), spinal cord injury (14%), multiple sclerosis (4%), and idiopathic (23%). Indications for BTX-A were urge urinary incontinence and refractory storage symptoms in 15 and 7 patients, respectively. 18/22 patients completed urodynamic studies (UDS) prior to BTX-A injections. Mean maximum cystometric capacity was 298 cc. Decreased compliance and detrusor overactivity were noted in 6 (33%) and 9 (50%) patients, respectively. Patients underwent injection of 200-300 units of BTX-A. Combined intradetrusor and intra-augment injections were done in 11 patients, the remaining 18 patients received only intradetrusor injections. 18 patients (82%) reported improvement in subjective parameters (frequency, urgency, incontinence). There was no significant difference in subjective outcome associated with site of injection (p¼0.5, chi-square). No patients had adverse events associated with systemic absorption of BTX-A. One patient had persistent detrusor overactivity, poor compliance, and hourglass configuration on post-BTX-A UDS, and required repeat augmentation cystoplasty. 17 (77%) patients underwent repeat injections; on average, patients underwent 3.3 injections with interval of 8.8 months between injections.
CONCLUSIONS: BTX-A injection was shown to subjectively improve refractory storage symptoms and continence after augmentation cystoplasty in the majority of patients. In this multi-institutional cohort, patients had good subjective response regardless of site of injection (combined versus intradetrusor only), and most patients went on to undergo repeat injections. Prospective studies are needed to better evaluate the efficacy and ideal sites of BTX-A injection in the setting of augmentation cystoplasty.
Source of Funding: NIH grant K12 DK0083014
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INTRODUCTION AND OBJECTIVES: The DIGNITY randomized controlled trials have lead botulinum toxin A to be licensed for neurogenic detrusor overactivity (NDO) but included only spinal cord injured and multiple sclerosis patients. To date, no data has been published regarding the efficacy of intradetrusor botulinum toxin injections (IDBTI) in patients with spinal dysraphism while these patients are injected in numerous centers in daily practice. The aim of the present study was to report the outcomes of IDBTI in spina bifida patients.
METHODS: All patients with spinal dysraphism who had undergone at least one IDBTI from 2002 ro 2016 in 14 centers were included retrospectively. Patients bleow the age of 16 years old were excluded to focus on an adult population. The primary endpoint was the success of injections, defined as as the combination of urgency, urinary incontinence and detrusor overactivity resolution. Datas collected included patients' characteristics, adverse events, and urodynamics parameters before and 6 weeks after IDBTI. The impact of poor compliance (defined as bladder compliance < 20 ml/cm H2O) and type of spinal dysraphism on outcomes was assessed through univariate analyses.
RESULTS: After exclusion of 53 children, 125 patients who underwent a total of 561 IDBTI courses were included (1 to 17 e1262 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 
